UY28602A1 - Compuestos quimicos - Google Patents
Compuestos quimicosInfo
- Publication number
- UY28602A1 UY28602A1 UY28602A UY28602A UY28602A1 UY 28602 A1 UY28602 A1 UY 28602A1 UY 28602 A UY28602 A UY 28602A UY 28602 A UY28602 A UY 28602A UY 28602 A1 UY28602 A1 UY 28602A1
- Authority
- UY
- Uruguay
- Prior art keywords
- chemical compounds
- compounds
- hsd1
- drugs
- inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
En la presente invención se describe el uso de compuestos de (I) en donde grupos variables son como se definen en la presente; en la fabricación de medicamentos para su uso en la inhibición de la 11B(beta)HSD1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0325745.8A GB0325745D0 (en) | 2003-11-05 | 2003-11-05 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
UY28602A1 true UY28602A1 (es) | 2005-06-30 |
Family
ID=29725933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY28602A UY28602A1 (es) | 2003-11-05 | 2004-11-05 | Compuestos quimicos |
Country Status (9)
Country | Link |
---|---|
US (1) | US20070219266A1 (es) |
EP (1) | EP1685101A1 (es) |
JP (1) | JP2007510702A (es) |
CN (1) | CN1902172A (es) |
AR (1) | AR046615A1 (es) |
GB (1) | GB0325745D0 (es) |
TW (1) | TW200519085A (es) |
UY (1) | UY28602A1 (es) |
WO (1) | WO2005047250A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100222316A1 (en) | 2004-04-29 | 2010-09-02 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US7880001B2 (en) | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
US8415354B2 (en) | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US8198331B2 (en) | 2005-01-05 | 2012-06-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
NZ555971A (en) | 2005-01-05 | 2011-01-28 | Abbott Lab | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US20090192198A1 (en) | 2005-01-05 | 2009-07-30 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
MX2007008238A (es) | 2005-01-05 | 2007-08-17 | Abbott Lab | Derivados de adamantilo como inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo 1. |
EP1866298A2 (en) | 2005-03-31 | 2007-12-19 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
WO2006131730A1 (en) * | 2005-06-06 | 2006-12-14 | Camurus Ab | Glp-1 analogue formulations |
US7579360B2 (en) | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
WO2006134481A1 (en) * | 2005-06-16 | 2006-12-21 | Pfizer Inc. | Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1 |
US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
KR101081293B1 (ko) | 2006-01-18 | 2011-11-08 | 에프. 호프만-라 로슈 아게 | 11 베타-에이치에스디1 억제제로서 티아졸 |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
TW200811170A (en) | 2006-06-27 | 2008-03-01 | Sanofi Aventis | Urea derivatives of tropane, their preparation and their therapeutic application |
FR2902790A1 (fr) * | 2006-06-27 | 2007-12-28 | Sanofi Aventis Sa | Derives d'urees de piperidine ou pyrrolidine,leur preparation et leur application en therapeutique |
TW200811158A (en) | 2006-06-27 | 2008-03-01 | Sanofi Aventis | Piperidine or pyrrolidine urea derivatives, their preparation and their therapeutic application |
CA2671378C (en) | 2006-12-19 | 2015-10-20 | F. Hoffmann-La Roche Ag | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives |
JP5736098B2 (ja) | 2007-08-21 | 2015-06-17 | アッヴィ・インコーポレイテッド | 中枢神経系障害を治療するための医薬組成物 |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
WO2009076404A1 (en) * | 2007-12-10 | 2009-06-18 | Epix Delaware, Inc. | Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor |
WO2009076512A1 (en) | 2007-12-11 | 2009-06-18 | Epix Delaware, Inc. | Carboxamidξ compounds and their use as chemokine receptor agonists |
GB0724251D0 (en) | 2007-12-12 | 2008-02-06 | Univ Edinburgh | Therapeutic compounds and their use |
GB0804685D0 (en) | 2008-03-13 | 2008-04-16 | Univ Edinburgh | Therapeutic compounds and their use |
TW200944526A (en) | 2008-04-22 | 2009-11-01 | Vitae Pharmaceuticals Inc | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
WO2011033255A1 (en) | 2009-09-16 | 2011-03-24 | The University Of Edinburgh | (4-phenyl-piperidin-1-yl)-[5-1h-pyrazol-4yl)-thiophen-3-yl]-methanone compounds and their use |
EP2563780B1 (en) | 2010-04-29 | 2015-05-06 | The University Of Edinburgh | 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11(beta)-hsd1 |
MX2014011419A (es) * | 2012-04-25 | 2014-11-25 | Hoffmann La Roche | Clorhidrato de (3,4-dicloro-fenil)-((s)-3-propil-pirrolidin-3-il)- metanona y procesos de manufacturacion. |
CA2937147A1 (en) * | 2013-12-20 | 2015-06-25 | Michael L. CORMAN | Substituted amino triazoles, and methods using same |
EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3499002A (en) * | 1968-06-20 | 1970-03-03 | Robins Co Inc A H | 1-carbamoyl-3-aroylpyrrolidines |
GB8401092D0 (en) * | 1984-01-16 | 1984-02-15 | Fujisawa Pharmaceutical Co | Piperidine derivatives |
PH23283A (en) * | 1986-02-26 | 1989-06-30 | Eisai Co Ltd | Piperidine derivative, pharmaceutical composition containing the same and method of use thereof |
DE4407136A1 (de) * | 1994-03-04 | 1995-09-07 | Thomae Gmbh Dr K | Aroyl-1-azacycloalkane, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung |
JPH10287671A (ja) * | 1997-04-14 | 1998-10-27 | Nippon Soda Co Ltd | イミダゾリルメチルフェニルまたはピリジルメチルフェニル誘導体およびその製造方法 |
SE0001899D0 (sv) * | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
GB0105772D0 (en) * | 2001-03-08 | 2001-04-25 | Sterix Ltd | Use |
WO2004033427A1 (en) * | 2002-10-11 | 2004-04-22 | Astrazeneca Ab | 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors |
-
2003
- 2003-11-05 GB GBGB0325745.8A patent/GB0325745D0/en not_active Ceased
-
2004
- 2004-11-04 EP EP04798370A patent/EP1685101A1/en not_active Withdrawn
- 2004-11-04 CN CNA2004800397491A patent/CN1902172A/zh active Pending
- 2004-11-04 US US10/578,230 patent/US20070219266A1/en not_active Abandoned
- 2004-11-04 WO PCT/GB2004/004641 patent/WO2005047250A1/en active Application Filing
- 2004-11-04 JP JP2006538921A patent/JP2007510702A/ja not_active Withdrawn
- 2004-11-05 UY UY28602A patent/UY28602A1/es not_active Application Discontinuation
- 2004-11-05 AR ARP040104086A patent/AR046615A1/es unknown
- 2004-11-05 TW TW093133933A patent/TW200519085A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP1685101A1 (en) | 2006-08-02 |
JP2007510702A (ja) | 2007-04-26 |
AR046615A1 (es) | 2005-12-14 |
US20070219266A1 (en) | 2007-09-20 |
GB0325745D0 (en) | 2003-12-10 |
TW200519085A (en) | 2005-06-16 |
WO2005047250A1 (en) | 2005-05-26 |
CN1902172A (zh) | 2007-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY28602A1 (es) | Compuestos quimicos | |
UY28603A1 (es) | Compuestos quimicos | |
BRPI0513310A (pt) | análogos de tetrapeptìdeo | |
CU23464B7 (es) | (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
ECSP088369A (es) | Novedosos derivados de 1-aza-bicicloalquilo para el tratamiento de trastornos psicóticos y neurodegenerativos | |
UY29372A1 (es) | Compuestos de bis arilo y hteroarilo sustituídos como antagonistas selectivos de 5htza | |
ECSP088536A (es) | DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR | |
GT200400274A (es) | Nuevos derivados de quinolina | |
ECSP088749A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
GT200200273A (es) | Moleculas pequeñas para el tratamiento del crecimiento celular anormal | |
CY1110813T1 (el) | Χημικες ενωσεις | |
UY29149A1 (es) | Tiazolil-dihidro-indazoles | |
GT200300296A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
ECSP045178A (es) | Compuestos de aril úrea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos | |
ECSP088932A (es) | Nuevos compuestos químicos | |
PA8539201A1 (es) | Pirido-pirimidinas 6-sustituidas | |
ECSP088145A (es) | Derivados bicíclicos como inhibidores de la cinasa p38 | |
CR9223A (es) | 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen | |
BRPI0509660A (pt) | compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias | |
PA8667201A1 (es) | Nuevos compuestos farmaceuticos | |
PA8616801A1 (es) | Compuestos de pirazolilo e imidazolilo biciclicos y uso de los mismos | |
GT200600199A (es) | Diarilsulfonas sulfonamidas y su uso | |
PA8618901A1 (es) | Biaril sulfonamidas y metodo para el uso de las mismas | |
UY29685A1 (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen. | |
UY28894A1 (es) | Derivados de pirimidina para tratar el crecimiento celular anómalo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20150605 |